Solascure - up 66%
In brief
- Began clinical trials in October 2021.
- Completed Series A raise of £15m, with funding from industry veterans, institutional venture and strategic investors, in August 2021.
- Selected for URGO Mentorship Program in 2019.
The company
Solascure are working to revolutionise wound care. Its proprietary technology leverages biomimicry and evidence-based medicine to develop treatments for patients with chronic wounds. Its product, Aurase® Wound Gel, is a hydrogel containing an enzyme – isolated and cloned from medical maggots – being developed to find a solution to inadequate debridement procedures.
The numbers
Access co-invested in SolasCure alongside a super angel with a weighted IRR of 66%. Their other investments include Geospock, Healx, and Gelmetix.
Find out more about SolasCure on their website.
Find out more about our fund, Access EIS.
See our quarterly highlights
Looking for a fund that does things differently?
Download our quarterly highlights here, with more information on the performance of our portfolio companies.
Register to learn
more about our data,
fund and venture capital
Related articles
4 min read
Access EIS investments for April 2022
See which innovative new startups SyndicateRoom and its super angels backed in March
Read article4 min read
Company Spotlight: StarStock.
Find out more about Access EIS portfolio company, StarStock, allows pubs, bars, clubs and hotels to order directly from brand owners.
Read article2 min read
Company Spotlight: Porotech.
Find out more about Access EIS portfolio company, Porotech, which is developing the next generation of Micro-LED display.
Read article7 min read
We managed 2 IPOs in 2021: here’s 3 key lessons and a note on EIS.
We helped two of our portfolio companies IPO in 2021. But what does the process involve, what did we learn, and why is it important to claim EIS?
Read article3 min read
Access EIS investments for March 2022
See which innovative new startups SyndicateRoom and its super angels backed in March
Read article